Cilcare appoints Camille Rochmann as Evidence, Value & Access Senior Manager

Montpellier, France, September 4^th 2025 : Cilcare, a biotechnology company specializing in auditory sciences, is pleased to announce the appointment of Camille Rochmann, PharmD, as Evidence, Value & Access Senior Manager. In this role, Camille will lead Cilcare’s strategy for evidence generation and market access, ensuring that innovation in hearing health is supported by robust data and aligned with regulatory and payer expectations from the earliest stages of development.

Camille brings over seven years of experience at Sanofi, where she worked on global and affiliate-level strategies in Health Economics and Outcomes Research (HEOR), particularly in the field of rare diseases. Based in Boston and Paris, she led initiatives in real-world evidence generation, regulatory engagement (EMA, FDA), and the design of patient-centered clinical endpoints to support product access and positioning.

At Cilcare, Camille will be responsible for developing and executing value and evidence strategies that support both clinical innovation and regulatory success. She will work closely with internal teams to incorporate patient-centered and payer-relevant endpoints into clinical trials, and guide health economics activities in compliance with global regulatory requirements.

“We are thrilled to welcome Camille to the Cilcare team,” said Celia Belline, CEO and Co-founder of Cilcare. “Camille’s strategic insights, scientific expertise, and deep understanding of market access will be instrumental in advancing our lead candidate CIL001 toward clinical and commercial success. Her contributions will also strengthen the positioning of our diagnostic tool for cochlear synaptopathy, helping us demonstrate its value to stakeholders and accelerate its adoption in the hearing health landscape.”

“I’m excited to join a company that is pushing boundaries in hearing health,” said Camille Rochmann. “Bringing effective and accessible treatments to patients with hearing disorders requires a strong alignment between scientific innovation and the evidence that payers, providers, and regulators need. I look forward to supporting Cilcare’s mission with a value-driven, evidence-based approach.”

Camille holds a Doctor of Pharmacy (PharmD) and a Master’s degree in Pharmacoeconomics & Market Access from Paris-Saclay University. Her appointment reflects Cilcare’s growing commitment to embedding market access strategy into every phase of product development and to ensuring the long-term success of its innovations — from diagnostics to therapeutics.

About Cilcare: Cilcare is a biotechnology company specializing in auditory sciences, developing cutting-edge solutions for the characterization, diagnosis, and treatment of hearing disorders and associated diseases. Founded in 2014 by three visionary entrepreneurs, Cilcare addresses global hearing health challenges by combining an advanced R&D platform, a promising drug candidate portfolio, and the use of artificial intelligence and machine learning to characterize various forms of hearing loss.

For the past 10 years, Cilcare has also made its technology available to industry leaders and researchers in Europe, the United States, and Asia to accelerate the development of drugs, gene and cell therapies, and medical devices for hearing disorders.

Compliments of Cilcare – a member of the EACCNY